A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery

Archive ouverte

Crouchet, Emilie | Bandiera, Simonetta | Fujiwara, Naoto | Li, Shen | El Saghire, Hussein | Fernández-Vaquero, Mirian | Riedl, Tobias | Sun, Xiaochen | Hirschfield, Hadassa | Jühling, Frank | Zhu, Shijia | Roehlen, Natascha | Ponsolles, Clara | Heydmann, Laura | Saviano, Antonio | Qian, Tongqi | Venkatesh, Anu | Lupberger, Joachim | Verrier, Eloi, R. | Sojoodi, Mozhdeh | Oudot, Marine, A. | Duong, François, H. T. | Masia, Ricard | Wei, Lan | Thumann, Christine | Durand, Sarah, C. | González-Motos, Victor | Heide, Danijela | Hetzer, Jenny | Nakagawa, Shigeki | Ono, Atsushi | Song, Won-Min | Higashi, Takaaki | Sanchez, Roberto | Kim, Rosa, S. | Bian, C. Billie | Kiani, Karun | Croonenborghs, Tom | Subramanian, Aravind | Chung, Raymond, T. | Straub, Beate, K. | Schuppan, Detlef | Ankavay, Maliki | Cocquerel, Laurence | Schaeffer, Evelyne | Goossens, Nicolas | Koh, Anna, P. | Mahajan, Milind | Nair, Venugopalan, D. | Gunasekaran, Ganesh | Schwartz, Myron, E. | Bardeesy, Nabeel | Shalek, Alex, K. | Rozenblatt-Rosen, Orit | Regev, Aviv | Felli, Emanuele | Pessaux, Patrick | Tanabe, Kenneth, K. | Heikenwälder, Mathias | Schuster, Catherine | Pochet, Nathalie | Zeisel, Mirjam, B. | Fuchs, Bryan, C. | Hoshida, Yujin | Baumert, Thomas, F.

Edité par CCSD ; Nature Publishing Group -

International audience. Abstract Chronic liver disease and hepatocellular carcinoma (HCC) are life-threatening diseases with limited treatment options. The lack of clinically relevant/tractable experimental models hampers therapeutic discovery. Here, we develop a simple and robust human liver cell-based system modeling a clinical prognostic liver signature (PLS) predicting long-term liver disease progression toward HCC. Using the PLS as a readout, followed by validation in nonalcoholic steatohepatitis/fibrosis/HCC animal models and patient-derived liver spheroids, we identify nizatidine, a histamine receptor H2 (HRH2) blocker, for treatment of advanced liver disease and HCC chemoprevention. Moreover, perturbation studies combined with single cell RNA-Seq analyses of patient liver tissues uncover hepatocytes and HRH2 + , CLEC5A high , MARCO low liver macrophages as potential nizatidine targets. The PLS model combined with single cell RNA-Seq of patient tissues enables discovery of urgently needed targets and therapeutics for treatment of advanced liver disease and cancer prevention.

Suggestions

Du même auteur

Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment

Archive ouverte | Roehlen, Natascha | CCSD

Background & aims: Despite recent approvals, the response to treatment and prognosis of patients with advanced hepatocellular carcinoma (HCC) remain poor. Claudin-1 (CLDN1) is a membrane protein that is expressed at tight junction...

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Archive ouverte | Hamdane, Nourdine | CCSD

Comment in Indelibly Stamped by Hepatitis C Virus Infection: Persistent Epigenetic Signatures Increasing Liver Cancer Risk. [Gastroenterology. 2019]. International audience. BACKGROUND & AIMS:Chronic hepatiti...

Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation

Archive ouverte | Crouchet, Emilie | CCSD

Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients, for which chemopreventive strategies are lacking. Recently, we developed a simple human cell-based system modeling a clinical prognostic liver si...

Chargement des enrichissements...